This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

C. Ann Merrifield net worth and biography

C. Merrifield Biography and Net Worth

Director of Lyra Therapeutics

Ann Merrifield currently serves as board director for a portfolio of public and private companies in the life sciences sector which include Flexion Therapeutics, Inc., InVivo Therapeutics Holdings Corp., and Veritas Genetics Inc.

Previously, she spent an 18-year career at Genzyme Corporation, a diversified global biotechnology company. While at Genzyme, Ann served as President, Genzyme Biosurgery, where she led global business strategy and operations across a portfolio of biologics and therapeutic devices. She also served as President, Genzyme Genetics, playing a key role in developing this start-up genetic diagnostics business and bringing it to profitability.

Following Genzyme from 2012-2014, she served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College.

What is C. Ann Merrifield's net worth?: The estimated net worth of C. Ann Merrifield is at least $58,565.76 as of June 10th, 2022. Ms. Merrifield owns 11,328 shares of Lyra Therapeutics stock worth more than $58,566 as of April 25th. This net worth estimate does not reflect any other assets that Ms. Merrifield may own. Learn More about C. Ann Merrifield's net worth.
How do I contact C. Ann Merrifield?: The corporate mailing address for Ms. Merrifield and other Lyra Therapeutics executives is 480 ARSENAL STREET, WATERTOWN MA, 02472. Lyra Therapeutics can also be reached via phone at 617-393-4600 and via email at [email protected]. Learn More on C. Ann Merrifield's contact information.
Has C. Ann Merrifield been buying or selling shares of Lyra Therapeutics?: C. Ann Merrifield has not been actively trading shares of Lyra Therapeutics over the course of the past ninety days. Most recently, on Friday, June 10th, C Ann Merrifield bought 4,000 shares of Lyra Therapeutics stock. The stock was acquired at an average cost of $5.05 per share, with a total value of $20,200.00. Following the completion of the transaction, the director now directly owns 11,328 shares of the company's stock, valued at $57,206.40. Learn More on C. Ann Merrifield's trading history.
Are insiders buying or selling shares of Lyra Therapeutics?: In the last year, Lyra Therapeutics insiders bought shares 3 times. They purchased a total of 5,441,248 shares worth more than $13,452,132.56. The most recent insider tranaction occured on November, 10th when insider Harlan Waksal bought 25,000 shares worth more than $74,000.00. Insiders at Lyra Therapeutics own 17.4% of the company. Learn More about insider trades at Lyra Therapeutics.
Information on this page was last updated on 11/10/2023.

C. Ann Merrifield Insider Trading History at Lyra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/10/2022	Buy	4,000	$5.05	$20,200.00	11,328
5/16/2022	Buy	328	$5.00	$1,640.00	7,328
5/13/2022	Buy	3,500	$4.81	$16,835.00	7,000
6/17/2021	Buy	3,500	$8.97	$31,395.00	3,500

C. Ann Merrifield Buying and Selling Activity at Lyra Therapeutics

Lyra Therapeutics Company Overview

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $5.17

$5.13

$5.28

50 Day Range

MA: $5.56

$4.96

$6.53

2 Week Range

Now: $5.17

$2.01

$6.79

Volume

105,302 shs

Average Volume

312,671 shs

Market Capitalization

$308.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad